Hot Investor Mandate: Corporate Venture Arm of Large Company Invests Up to $6M in Therapeutics & Therapeutic Platforms with Strategic Fit

6 Feb

A corporate venture capital arm of a global company invests to further the parent company’s future strategic position, rather than purely for financial returns.  The firm looks to make equity investments into emerging biotech companies with typical investments ranging from $1 million to $6 million, with additional capital reserved for follow on investments. The firm has no set allocations it plans to make over the next year but is actively reviewing new opportunities. The firm considers opportunities located around the globe.

The firm is looking for biopharmaceutical companies developing therapeutics and therapeutic platforms generally at the preclinical stage and is open to considering both small molecules, biologics, nucleic acid, and gene and cellular therapeutic approaches. The firm is interested in various indications including immunology and autoimmune diseases (rheumatology, dermatology and gastroenterology), neuroscience (only neurodegenerative diseases) and oncology. The firm is not investing in diagnostics, devices or healthcare IT.

The firm is looking for companies with experienced management teams with domain expertise. The firm strongly prefers board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: